Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25230525 | 0.85 | HDAC1 (0.50) | HRH3TLR7HDAC1NT5EPDE10A | |
| SCHEMBL17078418 | 0.85 | HDAC1 (0.47) | HRH3TLR7TLR9HDAC1NT5E | |
| SCHEMBL2395003 | 0.83 | TLR7 (0.50) | TLR7TLR9HDAC1NT5EPDE10A | |
| SCHEMBL30439903 | 0.83 | TLR7 (0.50) | TLR7TLR9HDAC1NT5EPDE10A | |
| SCHEMBL17078382 | 0.82 | PDE10A (0.45) | HRH3TLR7HDAC1NT5EPDE10A | |
| SCHEMBL28474961 | 0.82 | MTOR (0.51) | HRH3TLR7HDAC1NT5EPDE10A | |
| SCHEMBL9936540 | 0.81 | HDAC1 (0.46) | TLR7HDAC1NT5EPDE10ACNR2 | |
| SCHEMBL9936928 | 0.81 | HDAC1 (0.46) | HRH3TLR7HDAC1NT5EPDE10A | |
| SCHEMBL12537200 | 0.80 | TLR9 (0.48) | HRH3TLR7TLR9KDM4EALDH1A1 | |
| SCHEMBL337171 | 0.80 | CNR2 (0.45) | HRH3TLR7HDAC1NT5EPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125815-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116129-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | HRH3 3095/4885TLR7 2548/4885TLR9 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.